WallStSmart

Akso Health Group ADR (AHG)vsNatera Inc (NTRA)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Natera Inc generates 15437% more annual revenue ($2.31B vs $14.84M). AHG leads profitability with a 0.0% profit margin vs -9.0%. NTRA earns a higher WallStSmart Score of 31/100 (F).

AHG

Avoid

16

out of 100

Grade: F

Growth: 6.0Profit: 2.5Value: 6.0Quality: 7.5
Piotroski: 2/9Altman Z: 7.29

NTRA

Avoid

31

out of 100

Grade: F

Growth: 8.0Profit: 2.0Value: 5.0Quality: 6.5
Piotroski: 4/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

AHGUndervalued (+19.4%)

Margin of Safety

+19.4%

Fair Value

$1.75

Current Price

$1.98

$0.23 discount

UndervaluedFair: $1.75Overvalued

Intrinsic value data unavailable for NTRA.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AHG2 strengths · Avg: 10.0/10
Debt/EquityHealth
0.0010/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth
7.2910/10

Safe zone — low bankruptcy risk

NTRA1 strengths · Avg: 10.0/10
Revenue GrowthGrowth
39.8%10/10

Revenue surging 39.8% year-over-year

Areas to Watch

AHG4 concerns · Avg: 3.8/10
Price/BookValuation
8.6x4/10

Trading at 8.6x book value

Revenue GrowthGrowth
0.9%4/10

0.9% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$1.76B3/10

Smaller company, higher risk/reward

NTRA4 concerns · Avg: 2.8/10
Price/BookValuation
15.8x4/10

Trading at 15.8x book value

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Return on EquityProfitability
-14.3%2/10

ROE of -14.3% — below average capital efficiency

Profit MarginProfitability
-9.0%1/10

Currently unprofitable

Comparative Analysis Report

WallStSmart Research

Bull Case : AHG

The strongest argument for AHG centers on Debt/Equity, Altman Z-Score.

Bull Case : NTRA

The strongest argument for NTRA centers on Revenue Growth. Revenue growth of 39.8% demonstrates continued momentum.

Bear Case : AHG

The primary concerns for AHG are Price/Book, Revenue Growth, EPS Growth.

Bear Case : NTRA

The primary concerns for NTRA are Price/Book, EPS Growth, Return on Equity.

Key Dynamics to Monitor

AHG profiles as a value stock while NTRA is a hypergrowth play — different risk/reward profiles.

NTRA carries more volatility with a beta of 1.57 — expect wider price swings.

NTRA is growing revenue faster at 39.8% — sustainability is the question.

NTRA generates stronger free cash flow (38M), providing more financial flexibility.

Bottom Line

NTRA scores higher overall (31/100 vs 16/100) and 39.8% revenue growth. AHG offers better value entry with a 19.4% margin of safety. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Akso Health Group ADR

HEALTHCARE · MEDICAL DISTRIBUTION · China

Akso Health Group ADR is a leading entity in the healthcare sector, focused on delivering innovative medical solutions and comprehensive patient care services. The company utilizes advanced health technologies to exploit burgeoning opportunities in telehealth and personalized medicine, supported by a strong emphasis on research and development. With a solid business model and a highly proficient workforce, Akso Health Group represents a compelling investment opportunity for institutional investors looking to capitalize on the dynamic changes within the healthcare industry.

Visit Website →

Natera Inc

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

Natera, Inc., a diagnostic company, develops and markets molecular testing services globally. The company is headquartered in San Carlos, California.

Want to dig deeper into these stocks?